WallStSmart

The Cooper Companies, Inc (COO)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1454% more annual revenue ($65.77B vs $4.23B). MRK leads profitability with a 13.6% profit margin vs 5.6%. COO appears more attractively valued with a PEG of 0.68. COO earns a higher WallStSmart Score of 59/100 (C).

COO

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 3.5Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: 2.65

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COOUndervalued (+60.3%)

Margin of Safety

+60.3%

Fair Value

$209.19

Current Price

$65.42

$143.77 discount

UndervaluedFair: $209.19Overvalued
MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$119.60

$38.64 premium

UndervaluedFair: $80.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COO4 strengths · Avg: 8.3/10
Debt/EquityHealth
0.309/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

EPS GrowthGrowth
26.9%8/10

Earnings expanding 26.9% YoY

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

COO4 concerns · Avg: 2.3/10
Return on EquityProfitability
2.9%3/10

ROE of 2.9% — below average capital efficiency

Profit MarginProfitability
5.6%3/10

5.6% margin — thin

P/E RatioValuation
57.5x2/10

Premium valuation, high expectations priced in

Operating MarginProfitability
-2.9%1/10

Operating margin of -2.9%

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : COO

The strongest argument for COO centers on Debt/Equity, PEG Ratio, Price/Book. PEG of 0.68 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : COO

The primary concerns for COO are Return on Equity, Profit Margin, P/E Ratio. A P/E of 57.5x leaves little room for execution misses.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

COO carries more volatility with a beta of 0.87 — expect wider price swings.

COO is growing revenue faster at 7.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

COO scores higher overall (59/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Cooper Companies, Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?